Mirati Therapeutics, Inc. (NASDAQ:MRTX)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Thursday, MarketBeat Ratings reports. They currently have a $20.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 38.89% from the company’s previous close.

MRTX has been the topic of several other reports. Zacks Investment Research lowered shares of Mirati Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. ValuEngine raised shares of Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 15th. Oppenheimer Holdings, Inc. initiated coverage on shares of Mirati Therapeutics in a research report on Monday, September 18th. They issued an “outperform” rating and a $18.00 price objective on the stock. Citigroup Inc. reissued a “buy” rating and issued a $16.00 price objective (up from $8.00) on shares of Mirati Therapeutics in a research report on Tuesday, September 19th. Finally, Leerink Swann increased their price objective on shares of Mirati Therapeutics from $7.00 to $9.00 and gave the company a “market perform” rating in a research report on Friday, September 15th. Two analysts have rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $13.88.

Mirati Therapeutics (MRTX) traded down 1.39% during mid-day trading on Thursday, reaching $14.20. 474,872 shares of the company’s stock traded hands. Mirati Therapeutics has a 1-year low of $2.70 and a 1-year high of $15.50. The firm has a 50 day moving average of $8.95 and a 200 day moving average of $5.36. The firm’s market cap is $354.56 million.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/12/mirati-therapeutics-inc-mrtx-now-covered-by-hc-wainwright.html.

In related news, SVP Jamie Christensen sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $14.00, for a total transaction of $56,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. 5.10% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. Royce & Associates LP increased its position in Mirati Therapeutics by 88.7% during the second quarter. Royce & Associates LP now owns 251,100 shares of the biotechnology company’s stock worth $917,000 after acquiring an additional 118,063 shares during the period. Omega Advisors Inc. bought a new position in Mirati Therapeutics during the first quarter worth about $520,000. Bank of New York Mellon Corp increased its position in Mirati Therapeutics by 22.9% during the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock worth $328,000 after acquiring an additional 11,753 shares during the period. PDT Partners LLC bought a new position in Mirati Therapeutics during the second quarter worth about $200,000. Finally, KCG Holdings Inc. bought a new position in Mirati Therapeutics during the first quarter worth about $106,000. 60.17% of the stock is currently owned by institutional investors and hedge funds.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.